Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

France says hepatitis B vaccine benefits outweigh multiple sclerosis risks

This article was originally published in Scrip

Executive Summary

The pharmacovigilance committee of France's medicines regulator, Afssaps, has discounted the risk of a possible association between vaccination against hepatitis B and the risk of a first central demyelinating event in children that might indicate the early stages of multiple sclerosis. It concluded at its meeting on September 30th that the available evidence did not alter the benefit/risk profile of hepatitis B vaccination.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC030682

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel